0
Your cart

Your cart is empty

Books > Medicine

Buy Now

Examining the Impact of Real-World Evidence on Medical Product Development - Proceedings of a Workshop Series (Paperback) Loot Price: R1,675
Discovery Miles 16 750
Examining the Impact of Real-World Evidence on Medical Product Development - Proceedings of a Workshop Series (Paperback):...

Examining the Impact of Real-World Evidence on Medical Product Development - Proceedings of a Workshop Series (Paperback)

National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Drug Discovery, Development, and Translation; Edited by Carolyn Shore, Amanda Wagner Gee, Benjamin Kahn, Erin Hammers Forstag

 (sign in to rate)
Loot Price R1,675 Discovery Miles 16 750 | Repayment Terms: R157 pm x 12*

Bookmark and Share

Expected to ship within 12 - 17 working days

Donate to Gift Of The Givers

Randomized controlled trials (RCTs) have traditionally served as the gold standard for generating evidence about medical interventions. However, RCTs have inherent limitations and may not reflect the use of medical products in the real world. Additionally, RCTs are expensive, time consuming, and cannot answer all questions about a product or intervention. Evidence generated from real-world use, such as real-world evidence (RWE) may provide valuable information, alongside RCTs, to inform medical product decision making. To explore the potential for using RWE in medical product decision making, the National Academies of Sciences, Engineering, and Medicine planned a three-part workshop series. The series was designed to examine the current system of evidence generation and its limitations, to identify when and why RWE may be an appropriate type of evidence on which to base decisions, to learn from successful initiatives that have incorporated RWE, and to describe barriers that prevent RWE from being used to its full potential. This publication summarizes the discussions from the entire workshop series. Table of Contents Front Matter 1 Introduction 2 Perspectives on Real-World Evidence 3 Learning from Success 4 Barriers and Disincentives to the Use of Real-World Evidence and Real-World Data 5 Getting Unstuck: Mythbusting the Current System 6 When Is a Real-World Data Element Fit for Assessment of Eligibility, Treatment Exposure, or Outcomes? 7 How Tightly Should Investigators Attempt to Control or Restrict Treatment Quality in a Pragmatic or Real-World Trial? 8 Obscuring Intervention Allocation in Trials to Generate Real-World Evidence: Why, Who, and How? 9 Gaining Confidence in Observational Comparisons 10 Looking Ahead References Appendix A: Related Resources Appendix B: Workshop One Agenda Appendix C: Workshop Two Agenda Appendix D: Workshop Three Agenda

General

Imprint: National Academies Press
Country of origin: United States
Release date: May 2019
First published: 2019
Authors: National Academies of Sciences, Engineering, and Medicine • Health and Medicine Division • Board on Health Sciences Policy • Forum on Drug Discovery, Development, and Translation
Editors: Carolyn Shore • Amanda Wagner Gee • Benjamin Kahn • Erin Hammers Forstag
Dimensions: 229 x 152mm (L x W)
Format: Paperback
Pages: 230
ISBN-13: 978-0-309-48829-7
Categories: Books > Medicine > General
LSN: 0-309-48829-X
Barcode: 9780309488297

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners